Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 13 2022 - 9:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 7, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd,
Denmark, 07 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article
5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up
to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 3 May 2022, Novo Nordisk
will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.
Since the announcement 30 May 2022, the following transactions
have been made:
| |
Number of
B shares | | |
Average
purchase price | | |
Transaction
value, DKK | |
Accumulated, last announcement | |
| 1,394,689 | | |
| | | |
| 1,054,982,615 | |
30 May 2022 | |
| 95,000 | | |
| 771.22 | | |
| 73,266,109 | |
31 May 2022 | |
| 95,000 | | |
| 765.37 | | |
| 72,709,820 | |
1 June 2022 | |
| 90,000 | | |
| 764.25 | | |
| 68,782,375 | |
2 June 2022 | |
| 95,000 | | |
| 774.66 | | |
| 73,593,163 | |
3 June 2022 | |
| 90,000 | | |
| 781.05 | | |
| 70,294,441 | |
Accumulated under the programme | |
| 1,859,689 | | |
| | | |
| 1,413,628,524 | |
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions
stated above, Novo Nordisk owns a total of 13,921,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share
capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount
up to DKK 24 billion during a 12- month period beginning 2 February 2022. As of 3 June 2022, Novo Nordisk has since 2 February 2022 repurchased
a total of 12,181,818 B shares at an average share price of DKK 756.49 per B share equal to a transaction value of DKK 9,215,433,545
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and
YouTube.
Further information
Media: |
|
|
Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
Natalia Salomao Abrahao (US) |
+1 848 304 1027 |
niaa@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 51 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: June 7, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024